Table 1.
Characteristic | Value (n=229) |
---|---|
Mean (SD) age (years): | |
At transplant | 52.6 (10.3) |
At screening | 61.5 (6.9) |
Male sex | 151 (66) |
Time since transplant (years): | |
<5 | 97 (42) |
5-10 | 57 (25) |
10-15 | 35 (15) |
15-20 | 16 (7) |
>20 | 24 (10) |
Mean (SD) | 9.0 (8.4) |
Median | 6.5 |
Renal function: | |
Mean (SD) serum creatinine (µmol/L) | 122.2 (47.3) |
Mean (SD) MDRD eGFR (mL/min/1.73 m2) | 55.1 (19.3) |
Cause of end stage kidney disease: | |
Glomerulonephritis | 127 (55) |
Polycystic kidney disease | 32 (14) |
Diabetic nephropathy | 20 (9) |
Hypertension | 8 (3) |
Other | 36 (16) |
Unknown | 6 (3) |
Deceased donor | 189 (83) |
Second or subsequent transplant | 29 (13) |
Immunosuppressive drugs at time of screening: | |
Triple—ciclosporin based (+ MMF/azathioprine and steroids) | 24 (10) |
Triple—tacrolimus based (+ MMF/azathioprine and steroids) | 53 (23) |
Triple—mTOR inhibitor based (+ MMF/azathioprine and steroids) | 45 (20) |
Dual—ciclosporin based (+ MMF/azathioprine) | 35 (15) |
Dual—tacrolimus based (+ MMF/azathioprine) | 12 (5) |
Dual—mTOR inhibitor (+ MMF/azathioprine) | 10 (4) |
Dual—MMF/azathioprine + steroids | 25 (11) |
Other (including steroid or MMF alone, experimental agents) | 21 (9) |
Not on immunosuppression at time of screening | 1 (<1) |
Not recorded | 1 (<1) |
Current or former smoker | 86 (38) |
History of other significant medical conditions: | |
Cardiovascular disease | 93 (41) |
Diabetes | 81 (35) |
Chronic lung disease | 23 (10) |
Previous malignancy: | |
Non-melanoma skin cancer (SCC or BCC) | 75 (33) |
Other* | 20 (9) |
Antiplatelet or anticoagulant drug use: | |
Aspirin | 69 (30) |
Clopidogrel | 8 (3) |
Warfarin | 19 (8) |
BCC=basal cell carcinoma; MDRD eGFR=glomerular filtration rate estimated using four variable modification of diet in renal disease equation; MMF=mycophenolic acid derivative (mycophenolate mofetil or mycophenolic acid sodium); mTOR inhibitor=mammalian target of rapamycin inhibitor (sirolimus or everolimus); SCC=squamous cell carcinoma.
*Melanoma (n=4); prostate (n=4); bladder (n=3); cervical (n=2); head and neck (n=2); renal (n=2); endometrium (n=1); breast (n=1); lymphoma (n=1); leukaemia (n=1).